← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT07010692

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Trial Parameters

Condition Keratinocyte Carcinoma
Sponsor Bruce Robinson, MD
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-05-16
Completion 2030-05
Interventions
Tirbanibulin ointment 1%non-ablative fractional laser

Brief Summary

The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.

Eligibility Criteria

Inclusion Criteria: biopsy confirmed squamous and/or basal cell carcinoma not previously treated by another method. Exclusion Criteria: * Cannot be pregnant at the time of treatment

Related Trials